11192017Headline:

Denver, Colorado

HomeColoradoDenver

Email Staff Writer Staff Writer on LinkedIn Staff Writer on Twitter Staff Writer on Facebook
Staff Writer
Staff Writer
Contributor •

Taskforce Advises Caution Following Drug Trial Disaster

Comments Off

According to a report by ABC News, a joint taskforce, set up by the British Pharmaceutical Industry and BioIndustry Association, advised on new procedure to protect patients during drug trials, following a devastating trial that injured six people. The drug trial of TGN 1412, manufactured by the company TeGenero, shocked the community and pharmaceutical industry when it left six men critically ill last March. The taskforce recognized that the vast number of initial drug trials have very few problems, but in order to safeguard patients and the public from additional injury they recommended that during the early phase of testing, only one patient be given a new drug which stimulates the immune system. In addition, they advised the pharmaceutical industry carry out greater research to determine the correct dose, and then staggering the dosing levels.